Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

78.74 -0.26 (-0.33%)
Streaming Delayed Price Updated: 9:56 AM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation
From Alcon Inc. Investors
Via Business Wire
Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Alcon Inc. (NYSE: ALC) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance
From Alcon Inc. Investors
Via Business Wire
News headline image
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
News headline image
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Announces Results of 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
News headline image
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population 
Via MarketBeat
News headline image
Alcon Publishes Agenda for 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
News headline image
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
From Alcon Inc. Corporate
Via Business Wire
News headline image
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
From Alcon Inc. Investors
Via Business Wire
News headline image
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
From Lifecore Biomedical, Inc.
Via GlobeNewswire
News headline image
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Reports Third Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia
From Alcon Inc. Investors
Via Business Wire
News headline image
Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence
From Alcon Inc. Corporate
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Alcon Announces its Largest-Ever Scientific Program at the 41st Congress of the ESCRS, Showcasing New Data and Innovation to Support Ophthalmic Surgical Teams
From Alcon Inc. Corporate
Via Business Wire
News headline image
Alcon Reports Second Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
News headline image
Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
News headline image
Alcon Advances Company’s Social Impact Through Global Volunteerism
From Alcon Inc. Corporate
Via Business Wire
News headline image
Alcon Reports First Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
News headline image
New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision
From Alcon Inc. Investors
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.